Manali Kamdar, MD from University of Colorado Bristol Myers Squibb has received a positive opinion from the European Medicines Agency’s…
Browsing: Large B-cell Lymphoma
Odronextamab: ASH 2022 Won Seog Kim MD Prespecified Analysis ELM-2 in DLBCL By Won Seog Kim, MD How can Odronextamab…
Odronextamab: ASH 2022 Won Seog Kim MD Prespecified Analysis ELM-2 in DLBCL By Won Seog Kim, MD How can Odronextamab…
Liso-cel: ASH 2022 Jeremy Abramson vs. SOC SCT and ASCT in RR LBCL By Jeremy Abramson, MD What did the…
iFrame is not supported! Liso-cel: ASH 2022 Jeremy Abramson vs. SOC SCT and ASCT in RR LBCL By Jeremy Abramson,…
Liso-cel: ASH 2022 Jeremy Abramson vs. SOC SCT and ASCT in RR LBCL By Jeremy Abramson, MD What did the…
iFrame is not supported! Axicabtagene Ciloleucel (Axi-Cel) Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6 By Olalekan…
Axicabtagene Ciloleucel (Axi-Cel) Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6 By Olalekan Oluwole, MD, MPH, MBBS…
Lisocabtagene Maraleucel has been approved by the FDA for the second-line treatment of large B cell lymphoma LBCL Lisocabtagene Maraleucel…